Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy

Homayoun Tabandeh, Nauman A. Chaudhry, David S. Boyer, Veronica A. Kon-Jara, Harry W Flynn

Research output: Contribution to journalArticle

21 Scopus citations


Purpose: To evaluate the visual outcomes, choroidal neovascular complex status, and adverse events in patients with visually significant cataract and neovascular age-related macular degeneration (AMD) who had cataract surgery. Setting: Private practices, Beverly Hills, California, and New London, Connecticut, USA. Design: Case series. Methods: Data were abstracted from the medical records of patients with neovascular AMD treated by anti-vascular endothelial growth factor (anti-VEGF) therapy who had cataract surgery. The main outcome measures were Snellen corrected distance visual acuity (CDVA), perioperative adverse events, and status of the choroidal neovascular complex. Results: The study enrolled 30 eyes of 28 patients. The CDVA was 20/40 or better in 10% of eyes preoperatively and 40% postoperatively; 20/50 to 20/100 in 53% and 33%, respectively; and 20/200 or worse in 37% and 27%, respectively. The change in CDVA from preoperatively to postoperatively was statistically significant, with a mean change of 0.22 logMAR ± 0.27 (SD) at 2 months (P<.0001), 0.22 ± 0.36 logMAR at 6 months (P=.001), and 0.17 ± 0.54 logMAR at the last follow-up (P=.01). Patients received a mean of 0.32 injections per month postoperatively compared with 0.49 injections per month preoperatively. Perioperative macular adverse events did not occur in any eye. Conclusions: With regular evaluations and appropriate treatment with anti-VEGF agents, cataract surgery did not appear to be associated with an increased incidence of perioperative complications or macular adverse events. Financial Disclosures: Dr. Tabandeh is a consultant/advisor to Alcon and Allergan. Dr. Boyer is a consultant/advisor to Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer, and Optos and has received lecture fees from Allergan, Alcon, Genentech, and Pfizer. No other author has a financial or proprietary interest in any material or method mentioned.

Original languageEnglish
Pages (from-to)677-682
Number of pages6
JournalJournal of Cataract and Refractive Surgery
Issue number4
StatePublished - Apr 1 2012


ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Surgery

Cite this